Clinical Trial Update: Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Tarceva (erlotinib) in combination with AT-101 for advanced non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Tarceva (erlotinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Carcinoma, Non Small Cell Lung | Phase 1 | Status: WITHDRAWN